Drug Profile
KN 024
Alternative Names: KN-024Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Eye-disorders in China
- 11 Feb 2022 KN 024 is still in preclinical trials for Eye disorders in China (unspecified route) (Alphamab pipeline, February 2022)
- 12 Jul 2019 KN 024 is still in preclinical trials for Eye disorders in China (Alphamab pipeline, July 2019)